Alexandra van Vliet

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The design, synthesis, and initial biological evaluation of a doxorubicin prodrug that contains a dual tumor specific moiety, which allows enhanced tumor recognition potential, is reported. Both a tumor-specific recognition site and a tumor selective enzymatic activation sequence are incorporated in the prodrug. The first tumor-specific sequence is the(More)
  • 1